

POLYOXOMETALATES: INTRODUCTION TO A CLASS OF INORGANIC COMPOUNDS AND THEIR BIOMEDICAL APPLICATIONS

Bernold Hasenknopf

Laboratoire de Chimie Inorganique et Matériaux Moléculaires, Université Pierre et Marie Curie, Paris, France

TABLE OF CONTENTS

1. Abstract
2. Introduction
 - 2.1. Structure drawings
3. Overview of polyoxometalates
 - 3.1. Synthesis
 - 3.2. Classification
 - 3.3. Common structures of iso- and heteropolyoxometalates
 - 3.4. Functionalized POMs
4. Biological and medical activities
 - 4.1. Antiviral activities
 - 4.2. Antitumoral activities
 - 4.2.1. Polyoxomolybdates
 - 4.2.2. Polyoxotungstates
 - 4.3. Antibacterial activities
 - 4.4. Diabetes
5. Cell penetration
6. Conclusions
7. References

1. ABSTRACT

An increasing number of potential applications for polyoxometalates in human medicine have been reported in the literature. These inorganic complexes are composed of early transition metals (mainly molybdenum, tungsten and vanadium) and oxygen. The present review gives an introduction into the chemistry of these compounds, and an overview of the principal studies of their biological and biochemical effects and their therapeutic potential. The reported antitumoral and antibiotic properties of molybdates and tungstates *in vitro* and *in vivo* are compiled and discussed, as are their influences on the blood glucose level in diabetic animals. Aspects of antiviral activities and cell penetration are treated.

2. INTRODUCTION

Polyoxometalates (POMs) are a class of inorganic compounds which have fascinated chemists for almost two centuries. Indeed, the so called "molybdenum blues" were described by Berzelius as early as 1826, but only the last decades have witnessed the systematic synthesis and characterization of this ever growing family of compounds. (1) Polyoxometalates are negatively charged aggregates of transition metals (mainly Vanadium, Molybdenum and Tungsten) with oxygen. More precisely, they are typically composed of metal ions in their highest oxidation state bridged by oxo ligands (O^{2-}). Almost any other element can be incorporated into the POM framework, and this leads to a overwhelming diversity of structures and properties. (2-5) It is therefore not surprising that POMs have attracted interest from a

variety of disciplines, and nowadays applications in the fields of chemical analysis, catalysis, material science, nuclear waste treatment and medicine are developed. (6, 7) The last point might appear surprising, as inorganic pharmaceuticals are still rare compared to the far more common organic compounds. (8) The aim of this review is therefore to introduce the field of POMs to researchers outside the (inorganic) chemist community and to survey some of the biomedical studies that have appeared today. We are convinced that a closer exchange between chemists and biologists will boost the development of biomedical applications of POMs, giving rise to new possibilities in molecular biology and in diagnosis and therapy of diseases. Excellent reviews have been published on biological and medical applications of POMs. (9, 10) As each author emphasizes different aspects, the interested reader should refer also to those publications.

2.1. Structure drawings

POMs contain a fairly large number of atoms in a relatively compact, three-dimensional structure. The representation of all bonds of every atom is therefore very crowded and not always informative. Instead, chemists have adopted the polyhedral representation where each metal ion is in the center of a polyhedron with its ligands on the vertices. For instance, a hexacoordinated metal is represented by an octahedron and a tetraordinated metal by a tetrahedron. In condensed structures with bridging ligands, the polyhedra share vertices and edges, or more rarely faces. Figure 1 gives an example for the representations of $\alpha\text{-[Mo}_8\text{O}_{26}]^{4-}$.




Figure 1. Structure drawings of α -[Mo₈O₂₆]⁴⁻. a) Ball-and-stick representation. b) Polyhedral representation.

3. OVERVIEW OF POLYOXOMETALATES

3.1. Synthesis

In aqueous solution, transition metal cations are coordinated by aqua (H₂O), hydroxo (OH⁻) and oxo (O²⁻) ligands. The acidity of a coordinated ligand parallels the charge of the metal cation. The higher the positive charge of the metal, the easier the protons on the ligand dissociate. Therefore, the highly charged cations of fully oxidized metals of groups 5 and 6 (e.g. vanadium(V), molybdenum(VI), tungsten(VI)) form stable complexes with oxo ligands in aqueous alkaline solutions (VO₄³⁻, MoO₄²⁻, WO₄²⁻). On acidification, a condensation reaction takes place, which yields M-O-M bridges (for details see inorganic textbooks (11-13)). This process can be repeated.

Furthermore, an expansion of the coordination number (i.e. the number of attached atoms to a given metal ion) occurs, and condensed structures result. (14) The precise nature of the POM thus formed depends on the boundary conditions, i. e. stoichiometry, solvent, pH, temperature, concentration, counterions, and many different compounds can be created by systematic variation of these factors. In addition, the formation of coordination bonds is reversible. As a consequence, the oxo bridges in POMs can be cleaved by the addition of base, and many more compounds are obtained by controlled degradation. These

products are called lacunary POMs as opposed to plenary or saturated POMs. The derivatization of preformed POMs is now fairly well understood and rational syntheses of regiospecifically substituted Keggin and Dawson structures (see figure 2 below) have been developed. (15-17) In other respect, the linking of preorganized and transferable building blocks has afforded extremely large POMs. (18)

3.2. Classification

One can divide the family of POMs in several groups depending on their composition and structure. (2, 11, 12, 19) For the purpose of this review, it is sufficient to note the following classes. POMs of the general formula [M_mO_y]ⁿ⁻ containing only a transition metal and oxygen are called isopolyoxometalates. Compounds including a small number of additional elements [X_xM_mO_y]ⁿ⁻ (X = heteroelement, x smaller than m) belong to the sub-class of heteropolyoxometalates.

3.3. Common structures of iso- and heteropolyoxometalates

Among the different structures known for POMs, some are more common and are shown in Figure 2. The Lindqvist structure is adopted by hexametalates of the formula [M₆O₁₉]ⁿ⁻. It consists of an octahedral arrangement of six octahedra. Each octahedron (which represents a metal ion with its coordination sphere, as explained above) is sharing four edges with four neighboring octahedra. This is a very compact arrangement, and the Lindqvist structure can indeed be seen as a fragment of a cubic closed packed metal oxide.

The structures in Figure 2b and c exemplify the structural diversity of compounds with the same general formula [M₇O₂₄]ⁿ⁻. The bent structure in Figure 2b is adopted by the isopolymolybdate [Mo₇O₂₄]⁶⁻, the so called paramolybdate. Heteropolyoxometalates [XM₆O₂₄]ⁿ⁻ present the Anderson structure depicted in Figure 2c. Six edge-sharing octahedra are arranged into a planar hexagon around the central heteroatom. In this case, X is octahedrally coordinated. The most common structure with tetrahedrally coordinated heteroatoms is the Keggin ion of general formula [XM₁₂O₄₀]ⁿ⁻ (Fig. 2d). Four trimetallic groups are arranged around a central tetrahedron. Finally, the Dawson structure of [X₂M₁₈O₆₂]ⁿ⁻ (Fig. 2e) can be formally considered as the combination of the fragments of two Keggin ions. A trimetallic group is withdrawn on each Keggin ion, and the remaining fragments are associated.

As mentioned above, lacunary structures are obtained by the selective removal of one or more metal ions by addition of base. They present open coordination sites which can be occupied by other metal or non-metal atoms. This strategy is commonly used to modify the structure and properties of POMs.

3.4. Functionalized POMs

Although it is now a common practice to refer to functionalized POMs, there does not seem to be a general agreement on the scope of this expression which will be used here in the broadest sense. One can recognize four sub-classes of functionalized POMs. i) *Metal derivatives of lacunary POMs* can be properly viewed as functionalized




Figure 2. Polyhedral representations of some common polyoxometalate structures. a) $[M_6O_{19}]^{n-}$ (Lindqvist-structure), b) $[Mo_7O_{24}]^{6-}$, c) $[XM_6O_{24}]^{n-}$ (Anderson-structure), d) $[XM_{12}O_{40}]^{n-}$ (Keggin-structure), e) $[X_2M_{18}O_{62}]^{n-}$ (Dawson-structure).

POMs. Indeed several transition metal derivatives are catalytically active for epoxidations with various oxidants. (20) In other respect, derivatives such as $[PW_{11}O_{39}RhCH_2CO_2H]^{5-}$ (21) or $[\alpha\text{-}P_2W_{17}O_{61}Sn(CH_2)_2CO_2H]^{7-}$ (22) carry a terminal functional group which can be further derivatized. ii) A sizable number of *organic derivatives of POMs* have been reported. Among others, these include alkoxo, organosilyl and organophosphoryl derivatives. (23) Alkoxo derivatives have been obtained by a variety of methods including O-alkylation and esterification of POMs, and self-assembly reactions. (24) Organosilyl and organophosphoryl derivatives have been obtained by reacting organochlorosilanes and organophosphonic acids, respectively, on lacunary POMs. (25, 26) Moreover a number of organophosphoryl and organoarsonyl derivatives have also been obtained by self-assembly reactions. (23, 27) iii) POMs where some terminal oxo ligands have been replaced by other *multiply-bonded ligands* form a third sub-class of derivatives. These compounds have been obtained via Wittig-like net [2+2] reactions of Mo=O bonds or by self-assembly reactions, including reductive nitrosylation and related reactions. (23, 28) iv) *Organometallic derivatives of POMs* are a sub-class of organometallic oxides. (29) Derivatization of POMs is of interest as it can lead to the immobilization of catalytically active POMs and might facilitate the recognition of biological targets.

4. BIOLOGICAL AND MEDICAL ACTIVITIES

4.1. Antiviral activities

In 1970, a group in Paris around Chermann noticed an inhibitory effect of "silicotungstic acid supernatants (STAS)", a cell culture supernatant obtained in a procedure where silicotungstic acid was employed. (30, 31) They subsequently recognized that the inhibitor was the silicotungstate ion, (32) and this led to a systematic study of the antiviral activities of this and other polyanions. (33-38) A particular effective compound was the tungstoantimonate $(NH_4)_{19}[Sb_9W_{21}O_{86}]$ (HPA-23). (39-45)

The advent of AIDS has increased the search for antiviral agents, and encouraged many studies also with polyoxometalates. In particular the groups of Hill and Yamase are very active in this area. This work is beyond the scope of this paper, and the interested reader should refer to the pertinent literature. (10, 45-50)

4.2. Antitumoral activities

4.2.1. Polyoxomolybdates

Yamase and his coworkers recognized the antitumor activities of Anderson-type polyoxomolybdates and of heptamolybdates. (51, 52) They investigated in particular the compound $(NH_3^+Pr)_6[Mo_7O_{24}]$ (named PM-8 by the authors) *in vivo*. This compound significantly suppressed the tumor growth in mice bearing subcutaneously or intraperitoneally implanted methylcholanthrene-induced tumor (Meth A sarcoma) or MM-46 adenocarcinoma. (53) The compound $(NH_3^+Pr)_6[Mo_7O_{24}]$ was administered intraperitoneally daily for nine days following the implantation of the tumor cells. For instance, a dose of 100 mg/kg produced an Increase-in-Life Span

(ILS ^{footnote 1}) of 63 % for mice with subcutaneous implants of Meth A sarcoma, and of 167 % for those with MM-46 adenocarcinoma. Similarly, a dose of 50 mg/kg led to a remarkable ILS of 111% for intraperitoneal implants of Meth A sarcoma. The parallel comparative study with approved drugs 5-fluorouracil (5-FU) and 1-(4-amino-2-methylpyrimidin-5-yl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU) indicated that $(\text{NH}_3^i\text{Pr})_6[\text{Mo}_7\text{O}_{24}]$ has a higher antitumor activity and is less toxic to mice.

Furthermore, the effectiveness of $(\text{NH}_3^i\text{Pr})_6[\text{Mo}_7\text{O}_{24}]$ against the progressive growth of small human cancer xenografts (MX-1, OAT, CO-4) has been evaluated. (53, 54) Daily treatment started 17 days after the implant of a 2x2 mm graft. Ten intraperitoneal injections of 200 mg/kg $(\text{NH}_3^i\text{Pr})_6[\text{Mo}_7\text{O}_{24}]$ slowed down the tumor growth of human breast cancer MX-1 so that the average size of the tumor was only 27% of that of the control group after 46 days. No special risks to the mice were detected.

Promising antitumor activity of $(\text{NH}_3^i\text{Pr})_6[\text{Mo}_7\text{O}_{24}]$ was also reported against CO-4 human colon cancer and OAT human lung cancer xenografts. It is often difficult to cure completely patients with human breast, lung and colon cancer by chemotherapy because of their slow growth. The potency of $(\text{NH}_3^i\text{Pr})_6[\text{Mo}_7\text{O}_{24}]$ is therefore promising and deserves further investigations. In order to explore the structure-activity relationship of $(\text{NH}_3^i\text{Pr})_6[\text{Mo}_7\text{O}_{24}]$, chemical derivatives were tested for Meth A sarcoma inhibiting activity. $(\text{NH}_3^i\text{Pr})\text{Cl}$ was ineffective, whereas the activities of $(\text{NH}_4)_6[\text{Mo}_7\text{O}_{24}]$ and $\text{K}_6[\text{Mo}_7\text{O}_{24}]$ are comparable to that of $(\text{NH}_3^i\text{Pr})_6[\text{Mo}_7\text{O}_{24}]$. This shows that the antitumor activity is associated with the polyoxomolybdate anion, and the cation possibly determines the solubility of the compound, hence its bioavailability. A mixture of reduced species $[\text{H}_x\text{Mo}_7\text{O}_{24}]^{6-}$ ($x = 1$ or 2) with one or two Mo^V atoms can be obtained by photoreduction of $(\text{NH}_3^i\text{Pr})_6[\text{Mo}_7\text{O}_{24}]$ in aqueous solution. The reduced mixture showed the same cancerostatic potency against MX-1 human breast xenografts as the fully oxidized precursor $(\text{NH}_3^i\text{Pr})_6[\text{Mo}_7\text{O}_{24}]$. However, it had a far higher toxicity to the host and resulted in the death of the mice during the experiment. Based on the strong toxic effect of reduced heptamolybdate, the authors have proposed a mechanism for the antitumor action of $(\text{NH}_3^i\text{Pr})_6[\text{Mo}_7\text{O}_{24}]$. The $[\text{Mo}_7\text{O}_{24}]^{6-}$ species would be reduced to $[\text{H}_x\text{Mo}_7\text{O}_{24}]^{6-}$ after thermal activation of an oxygen-to-molybdenum-charge-transfer. The reduced species would then be reoxidized by reduction of the tumor cell, causing cell lysis. This hypothesis can be correlated with the study of DNA binding of $(\text{NH}_3^i\text{Pr})_6[\text{Mo}_7\text{O}_{24}]$. It was shown that the heptamolybdate binds non-specifically to single and double-stranded DNA with little recognizable modifications of the DNA structure. (55) The cytotoxicity should therefore not result from interaction with DNA.

4.2.2. Polyoxotungstates

Antitumor activities of a variety of polyoxotungstates are mentioned in the scientific literature or in patents. (56-60) In the last few years, Liu, Pope and their co-workers have investigated the cytotoxic properties of many heteropolyoxotungstates against cancer cell lines *in vitro*. In order to allow a comparison of their separately published work, the reported IC_{50} ^{footnote 2} values have been recalculated in μM (micromolar) and compiled in Table 1. The authors focused mainly on organic derivatives of heteropolyoxotungstates containing RSn or CpTi (Cp = cyclopentadienyl) groups.

Attempts have been made to correlate the cytotoxicity of the compounds with the potential of the first reduction process. Within several series of closely related compounds, it was found that the sequence of IC_{50} values is consistent with the order of the reduction potential: the higher the reduction potential, the higher their cytotoxicity. (65) However, this correlation cannot be generalized. Indeed, structure and composition clearly also play an important role in determining the activity. Furthermore, the encapsulation of $[\text{CoW}_{11}\text{TiO}_{40}]^{8-}$ in starch nanoparticles enhances considerably its activity against tumor cells. (64) It was shown that encapsulation increases the cell penetration of $[\text{CoW}_{11}\text{TiO}_{40}]^{8-}$, and it can therefore be assumed that the higher efficiency is due to a higher concentration of the heteropolytungstate inside the cell. Organic substituents on the polyoxometalate core might have the same effect, (10, 65) but this hypothesis still needs to be verified. Obviously, further investigations are necessary to elucidate the mechanism of the cytotoxicity of polyoxotungstates *in vitro*, and to establish a structure-activity relationship. Few data are available on the antitumor activity of polyoxotungstates *in vivo*. Yamase reported in his patent applications the growth inhibition of Meth A tumors in mice by rare earth-containing decatungstates. (56, 58) For instance, the intraperitoneal uptake of $\text{Na}_9[\text{EuW}_{10}\text{O}_{36}]$ resulted in a slower tumor growth. After administration of 100 mg/kg/day for 9 days, the tumor weight was only 44% of that of the control group. Liu found inhibitory rates in the same order of magnitude for $[\text{CoW}_{11}\text{TiO}_{40}]^{8-}$ taken orally against subcutaneous implants of SSMC-7721 (liver), HL-60 (leukemia) and HLC (colon) cancer cells in rats. (65) Thus, the *in vivo* activity of $[\text{CoW}_{11}\text{TiO}_{40}]^{8-}$ resembles that of antitumor drugs CP (cyclophosphamide) and 5-FU (5-fluorouracil), but its toxicity was found to be much lower. The LD_{50} of $[\text{CoW}_{11}\text{TiO}_{40}]^{8-}$ is 2898 mg/kg, as compared to 94 mg/kg and 230 mg/kg for CP and 5-FU respectively by oral uptake in rats. (69)

4.3. Antibacterial activities

Beta-lactam antibiotics such as penicillins and cephalosporins hinder the construction of the cell wall in bacteria. They are by far the largest class of antibiotic drugs used. Therefore the increasing resistance of bacteria to these drugs represents a major health problem today. Many bacteria produce beta-lactamases. These enzymes hydrolyse the beta-lactam ring of the antibiotics, which makes the drug ineffective. The combination of beta-lactam antibiotics with a beta-lactamase inhibitor such as

Table 1. IC₅₀ values in *microM* for different heteropolyoxotungstates on tumor cells *in vitro*

Compound	Cancer Cell Line		Reference
	SSMC-7721	HeLa	
<i>alpha</i> -[(CpTi) ₃ Si ₃ W ₉ O ₃₇] ⁷⁻	7.8	14.0	61
<i>beta</i> -[(CpTi) ₃ Si ₃ W ₉ O ₃₇] ⁷⁻	6.7	12.1	61
<i>alpha</i> -[(CpTi) ₃ Ge ₃ W ₉ O ₃₇] ⁷⁻	4.0	7.6	61
<i>beta</i> -[(CpTi) ₃ Ge ₃ W ₉ O ₃₇] ⁷⁻	8.4	9.1	61
<i>gamma</i> -[(CH ₃ OOCCH ₂ CH ₂ Sn) ₂ SiW ₁₀ O ₃₈] ⁶⁻	20.2	24.5	62
<i>gamma</i> -[(CH ₃ OOCCH(CH ₃)CH ₂ Sn) ₂ SiW ₁₀ O ₃₈] ⁶⁻	19.0	23.2	62
<i>gamma</i> -[(NCCH ₂ CH ₂ Sn) ₂ SiW ₁₀ O ₃₈] ⁶⁻	15.7	17.8	62
<i>gamma</i> -[(C ₅ H ₅ Ti) ₂ SiW ₁₀ O ₃₈] ⁶⁻	4.4	8.8	62
<i>gamma</i> -[(C ₅ H ₅ Zr) ₂ SiW ₁₀ O ₃₈] ⁶⁻	13.2	20.5	62
[(CH ₃ OOCCH ₂ CH ₂ Sn) ₂ PW ₁₀ O ₃₈] ⁵⁻	17.2	21.7	63
[(CH ₃ OOCCH(CH ₃)CH ₂ Sn) ₂ PW ₁₀ O ₃₈] ⁵⁻	16.7	21.1	63
[(NCCH ₂ CH ₂ Sn) ₂ PW ₁₀ O ₃₈] ⁵⁻	10.4	15.5	63
[CoW ₁₁ TiO ₄₀] ⁸⁻	7.1	6.1, 14.1	64, 65
[CoW ₁₁ TiO ₄₀] ⁸⁻ starch encapsulated	-	1.2	64
[(C ₅ H ₅ Ti)CoW ₁₁ O ₃₉] ⁷⁻	3.2	11.5	65
[(CH ₃ OOCCH ₂ CH ₂ Sn) ₃ (PW ₉ O ₃₄) ₂] ⁹⁻	8.7	9.1	66
[(CH ₃ OOCCH(CH ₃)CH ₂ Sn) ₃ (PW ₉ O ₃₄) ₂] ⁹⁻	7.3	8.3	66
[(CH ₃ OOCCH ₂ CH ₂ Sn)PW ₁₁ O ₃₉] ⁴⁻	21.5	25.4	66
[(CH ₃ OOCCH(CH ₃)CH ₂ Sn)PW ₁₁ O ₃₉] ⁴⁻	20.8	24.9	66
[(CH ₃ OOCCH ₂ CH ₂ Sn)P ₂ W ₁₇ O ₆₁] ⁷⁻	18.3	19.1	66
[(CH ₃ OOCCH(CH ₃)CH ₂ Sn)P ₂ W ₁₇ O ₆₁] ⁷⁻	16.7	18.3	66
<i>alpha</i> -[(CH ₃ OOCCH ₂ CH ₂ Sn) ₃ SiW ₉ O ₃₇] ⁷⁻	28.1	28.8	67
<i>beta</i> -[(CH ₃ OOCCH ₂ CH ₂ Sn) ₃ SiW ₉ O ₃₇] ⁷⁻	19.1	24.9	67
<i>alpha</i> -[(CH ₃ OOCCH(CH ₃)CH ₂ Sn) ₃ SiW ₉ O ₃₇] ⁷⁻	27.5	28.4	67
<i>beta</i> -[(CH ₃ OOCCH(CH ₃)CH ₂ Sn) ₃ SiW ₉ O ₃₇] ⁷⁻	18.7	24.2	67
<i>alpha</i> -[(NCCH ₂ CH ₂ Sn) ₃ SiW ₉ O ₃₇] ⁷⁻	13.8	24.3	67
<i>beta</i> -[(NCCH ₂ CH ₂ Sn) ₃ SiW ₉ O ₃₇] ⁷⁻	9.5	21.7	67
<i>alpha</i> -[(CH ₃ OOCCH ₂ CH ₂ Sn) ₃ (SiW ₉ O ₃₄) ₂] ¹¹⁻	10.8	15.6	67
<i>beta</i> -[(CH ₃ OOCCH ₂ CH ₂ Sn) ₃ (SiW ₉ O ₃₄) ₂] ¹¹⁻	9.4	14.0	67
<i>alpha</i> -[(NCCH ₂ CH ₂ Sn) ₃ (SiW ₉ O ₃₄) ₂] ¹¹⁻	5.2	11.1	67
<i>beta</i> -[(NCCH ₂ CH ₂ Sn) ₃ (SiW ₉ O ₃₄) ₂] ¹¹⁻	3.6	10.0	67
[(C ₅ H ₅ Ti)CoW ₁₁ O ₃₉] ⁷⁻	3.2	11.5	65
[(C ₅ H ₅ Ti)GeW ₁₁ O ₃₉] ⁵⁻	15.7	17.8	68
[(C ₅ H ₅ Ti)GaW ₁₁ O ₃₉] ⁵⁻	14.0	15.8	68
[(C ₅ H ₅ Ti)BW ₁₁ O ₃₉] ⁶⁻	12.9	14.6	68

clavulanic acid (for example Augmentin®) can restore the antibiotic effectiveness. On the other hand, hydrolytically stable penicillins such as methicillin and oxacillin have been developed. Bacteria were developing resistance against these antibiotics by modifying their Penicillin-Binding-Proteins (PBP). For instance Methicillin-Resistant-Staphylococcus Aureus (MRSA) strains produce the PBP variant PBP 2', which plays the same role in the construction of the cell wall as PBP, but is insensitive to beta-lactams. These penicillin-resistant bacteria represent a very serious threat to humans, in particular in intensive care units, and much effort is devoted to find effective antibiotics against MRSA infections.

In 1993, Tajima reported the effect of an aged mixture of tungstate and phosphate in combination with beta-

lactam antibiotics. (70) He discovered that a factor (named "Factor T" for Tungstate) greatly enhanced the antibacterial effect of the drug in MRSA strains, but there was no synergism of factor T with other classes of antibiotics, nor any effect on other groups of bacteria. He subsequently studied the mechanism of action of Factor T, and found that it reduced the amount of PBP 2', and thus sensitized the MRSA strains to beta-lactams. (71) Factor T was finally identified as the lacunary Keggin polyoxotungstate [PW₁₁O₃₉]⁷⁻, (72) and an extended investigation together with Yamase on the synergistic effect of more than 70 polyoxometalates in combination with beta-lactam antibiotics followed. (73, 74) Whereas almost no polyoxomolybdate, nor polyoxovanadate exhibited a significant effect in combination with oxacillin on MRSA strains SR3605 and ATCC43300, almost all polyoxotungstates

Table 2. The antibacterial effects of polyoxotungstates alone (MIC) and in combination with oxacillin (FIC) against two different MRSA strains (73, 74)

Complex	MIC (microg/mL)		FIC	
	SR3605	ATCC43300	SR3605	ATCC43300
<i>Keggin Ions</i>				
Na ₃ [PW ₁₂ O ₄₀] \cdot n H ₂ O	3200	3200	0.156	0.062
Na ₄ [SiW ₁₂ O ₄₀] \cdot n H ₂ O	3200	3200	0.094	0.019
K ₅ [BW ₁₂ O ₄₀] \cdot 15 H ₂ O	800	800	0.156	0.094
K ₇ [PTi ₂ W ₁₀ O ₄₀] \cdot 6 H ₂ O	12800	3200	0.047	0.063
K ₅ [PVW ₁₁ O ₄₀] \cdot 6 H ₂ O	800	400	0.156	0.094
K ₆ [BVW ₁₁ O ₄₀] \cdot n H ₂ O	800	200	0.094	0.156
K ₆ [PV ₃ W ₉ O ₄₀] \cdot n H ₂ O	3200	1600	0.094	0.094
K ₆ [CoW ₁₂ O ₄₀] \cdot n H ₂ O	3200	1600	0.078	0.094
(⁴ Pr ₂ NH ₂) ₅ [PTiW ₁₁ O ₄₀] \cdot 4 H ₂ O	12800	3200	0.039	0.031
K ₅ [PV ₂ W ₁₀ O ₄₀] \cdot n H ₂ O	3200	1600	0.156	0.063
K ₅ [SiVW ₁₁ O ₄₀] \cdot n H ₂ O	3200	800	0.125	0.031
K ₆ H[SiV ₃ W ₉ O ₄₀] \cdot 3 H ₂ O	6400	1600	0.125	0.020
K ₆ [H ₂ SiNiW ₁₁ O ₄₀] \cdot n H ₂ O	6400	3200	0.078	0.012
<i>Monovacant Keggin Ions</i>				
<i>alpha</i> -K ₇ [PW ₁₁ O ₃₉] \cdot n H ₂ O (Fator T)	12800	6400	0.063	0.035
<i>Trivacant Keggin Ions</i>				
<i>alpha</i> -B-Na ₉ [PW ₉ O ₃₄] \cdot n H ₂ O	12800	12800	0.047	0.031
<i>beta</i> -A-Na ₉ [HSiW ₉ O ₃₄] \cdot 23 H ₂ O	12800	6400	0.094	0.018
<i>alpha</i> -B-Na ₉ [SbW ₉ O ₃₃] \cdot 19.5 H ₂ O	3200	1600	0.156	0.156
<i>Decatungstometalates</i>				
Na ₉ [EuW ₁₀ O ₃₆] \cdot 32 H ₂ O	3200	1600	0.188	0.313
K ₆ [GdW ₁₀ O ₃₆] \cdot 20 H ₂ O	3200	1600	0.313	0.281
<i>Anderson Ions</i>				
K _{5,5} H _{1,5} [SbW ₆ O ₂₄] \cdot 6 H ₂ O	12800	12800	0.156	0.063
K ₆ Na ₂ [MnW ₆ O ₂₄] \cdot 12 H ₂ O	6400	3200	0.281	0.281
<i>Giant Polyoxotungstates</i>				
Na ₂₇ [NaAs ₄ W ₄₀ O ₁₄₀] \cdot n H ₂ O	400	400	0.281	0.156
K ₁₈ [KSb ₉ W ₂₁ O ₈₆] \cdot n H ₂ O	200	400	0.313	0.281
<i>Wells-Dawson Ions</i>				
K ₆ [P ₂ W ₁₈ O ₆₂] \cdot 14 H ₂ O	200	200	0.070	0.023
Na ₉ [P ₂ W ₁₅ Nb ₃ O ₆₂] \cdot 23 H ₂ O	800	800	0.141	0.023
Na ₁₂ [P ₂ W ₁₅ O ₅₆] \cdot 18 H ₂ O	200	100	0.133	0.039
K ₁₀ [P ₂ W ₁₇ O ₆₁] \cdot 15 H ₂ O	200	100	0.141	0.063

showed synergism. This result can be correlated with the amount of polyoxometalates found inside the cells of MRSA strains MRS394-1. (74) When these cells grown to a stationary phase were treated with 100 microg/mL of Na₃[PW₁₂O₄₀] for 20 min, the amount of tungsten found inside the cells (mainly in the cell membrane) was 1.05 \pm 0.18 mg/g dry weight of cell (6 micromol/g). With the isostructural molybdate Na₃[PMo₁₂O₄₀], only 0.05 \pm 0.02 mg/g dry weight of cell (0.5 micromol/g) of molybdenum are incorporated into the cell. Metavanadate and hexaniobate are also absorbed to a lesser extent by the cells than the examined polyoxotungstates. However, there are too few studies of isostructural polyoxometalates to draw conclusions about the

relationship between composition and activity.

The synergistic potency of polyoxotungstates is decreased in the presence of polycations such as polylysine or protamine sulfate, which are likely to form ion pairs with the negatively charged polyoxotungstates. None of the factors charge, size or structure correlates with the FIC^{footnote 3} index, taken as a measure for the synergism of the POMs with beta-lactam antibiotics. This is expected, as not all of the compounds investigated are stable in the bacterial growth medium, and the actual active species remains unknown in such cases. However, some trends are apparent. Decatungstates, Andersontype compounds and large polyoxotungstates have generally a higher FIC index, i.e. lower synergistic efficiency than Keggin-type

compounds. The lacunary Keggin species $[\text{PW}_{11}\text{O}_{39}]^{7-}$ seems to be more efficient than its parent saturated compound $[\text{PW}_{12}\text{O}_{40}]^{3-}$. This is surprising as the latter hydrolyzes rapidly at near neutral pH to yield the lacunary complex and tungstate. In the same way, $[\text{SiW}_{11}\text{O}_{39}]^{8-}$ is formed from $[\text{SiW}_{12}\text{O}_{40}]^{4-}$. The lacuna itself is not required for antibacterial activity, as a large number of substituted Keggin ions $[\text{MSiW}_{11}\text{O}_{39}]^{(8-n)-}$ where the lacuna is filled with another transition metal M^{n+} , are more active than $[\text{SiW}_{11}\text{O}_{39}]^{8-}$. (75) The author concluded that $[\text{Co}^{\text{II}}\text{SiW}_{11}\text{O}_{39}]^{6-}$ represents the best compromise between toxicity and sensitizing effect. He further confirmed its suppressive effect on PBP production. (76) In fact, $[\text{Co}^{\text{II}}\text{SiW}_{11}\text{O}_{39}]^{6-}$ not only markedly reduced the amount of PBP 2', but also that of ordinary PBP 1-4. He also confirmed that the sensitizing effect of $[\text{SiW}_{11}\text{O}_{39}]^{8-}$ is due to reduced expression of PBP 2'. (77) It is noteworthy that the presence of small and lipophilic cations increase the sensitizing effect of $[\text{SiW}_{11}\text{O}_{39}]^{8-}$.

Selected Keggin ions were also tested together with oxacillin against Methicillin Susceptible Staphylococcus Aureus (MSSA) strains. (73) The enhancement of the antibiotic activity of oxacillin against these bacteria is considerably lower than in the case of MRSA strains, suggesting that the synergistic effect of polyoxotungstates with oxacillin is selective for MRSA. The Keggin ion $[\text{PTi}_2\text{W}_{10}\text{O}_{40}]^{7-}$ inhibits the formation of PBP2' in the MRSA strains ATCC43300 (73) and MRS3941 (74), as it was found for Factor T, (71) and for $[\text{Co}^{\text{II}}\text{SiW}_{11}\text{O}_{39}]^{6-}$ (76) and this would explain the observed antibacterial selectivity. Furthermore, it was found that $[\text{PTi}_2\text{W}_{10}\text{O}_{40}]^{7-}$ depresses the production of beta-lactamases, which contributes also to the synergistic effect with beta-lactam antibiotics. No synergism was found with other antibiotics.

In the context of the effect of POMs on the production of beta-lactamases, a preliminary note by Davies should be considered. He reported the induction of beta-lactamases expression in Bacillus Licheniformis upon addition of vanadate, tungstate or molybdate to the growth medium. (78) The composition of the medium favors the formation of POMs. It would therefore be of interest to check the influence of POMs on the production of beta-lactamases in different cell lines.

Besides this synergistic effect of polyoxotungstates, Yamase reported also an antibacterial effect of polyoxovanadates against six strains of penicillin resistant Streptococcus pneumonia. (79) The vanadates have MICs in the range of 4-32 $\mu\text{g}/\text{mL}$. In comparison, a selection of 9 polyoxotungstates and polyoxomolybdates have MICs in the range of 500-8000 $\mu\text{g}/\text{mL}$. The effect of the vanadates seems to be limited to Streptococcus pneumonia, as the activity against other pathogenic bacteria such as MRSA, MSSA, coagulase-negative staphylococci, Enterococcus faecalis, Escherichia coli and Pseudomonas aeruginosa was negligible.

The polyoxometalates examined so far for their antibacterial activity were too toxic to envision their clinical use, although their MRSA inhibition is patented. (80) Nevertheless, their use as a tool in microbiology laboratories is a conceivable application. (81)

4.4. Diabetes

Diabetes mellitus is the name given to a multiple group of disorders in the carbohydrate, protein and fat metabolism, characterized by a high blood glucose level. (82, 83) It is associated with insulin deficiency (Type I, insulin-dependent-diabetes-mellitus) or insulin resistance (Type II, non-insulin-dependent-diabetes-mellitus). Insulin is a peptidic hormone synthesized by the pancreatic beta-cells. Because type II diabetes represent around 90% of all cases, and also because insulin can not be administered orally, the development of new, preferentially oral, treatments is an important goal in pharmaceutical research. In the 1980's, the insulin-mimetic effect of vanadium salts was recognized in cells and in animal models of diabetes. (84-86) A large number of vanadium (IV and V) compounds with different organic ligands have been tested, and the results have been reviewed extensively. (87, 95) Although it is established that orally administered vanadium complexes alleviate the symptoms of diabetes also in human beings, (96, 97) their mode of action is not fully understood. It is commonly admitted that vanadium does not replace insulin, but enhances its action through competitive inhibition of regulatory protein phosphatases in the insulin signaling system.

The similarities of molybdate $[\text{MoO}_4]^{2-}$ and tungstate $[\text{WO}_4]^{2-}$ with vanadate $[\text{VO}_4]^{3-}$ prompted a spanish group around Guinovart to study their effect on the glucose metabolism in isolated hepatocytes. (98) They found similar, although less strong effects for molybdate and tungstate. In a series of studies with animal models for type I and type II diabetes (Streptozotocin-induced diabetic, Neonatally Streptozotocin-induced, and Zucker Diabetic Fatty rats), they established the antidiabetic effect of tungstate *in vivo*. (99-101) These animal models have a more or less impaired hepatic glucose metabolism. Orally administered tungstate decreases the blood glucose level in these diabetic animals, but not in healthy animals. However, conclusions for the possible treatment of diabetes in human beings are premature, because the long-term effects depend largely on the animal model. In another animal model (Streptozotocin-Nicotinamid induced) with a reduced pancreatic beta-cell mass, and with a normal hepatic glucose metabolism, no modification of the hyperglycemia was observed. Only a transient reduction of the glucose intolerance occurred. (102) These results suggest that tungstate is acting at the hepatic level, which is correlated with the inhibition of glucose-6-phosphatase (103) and with the glycogen synthesis activation (104) by tungstate. But as it is the case for vanadate, different mechanisms are most likely responsible for the normalization of glycaemia

Table 3. Trends in insulin-mimetic effects of polyoxotungstates (106)

Entry	Compound	Concentration (mM)	Blood glucose level relative to untreated group	Glucose lowering effect compared to NaVO ₃	Body weight loss compared to NaVO ₃ treated group
1	Na ₃ [a-PW ₁₂ O ₄₀] \cdot 8H ₂ O	4.56	+	--	--
2	K ₆ [<i>alpha</i> -P ₂ W ₁₈ O ₆₂] \cdot 10H ₂ O	3.03	-	+	-
3	Na ₂ WO ₄ \cdot 2H ₂ O	54.60	-	≈	--
4	K ₄ [<i>alpha</i> -PMo ₁₁ V ^V O ₄₀] \cdot 5H ₂ O	3.31	+	--	--
5	K ₄ [<i>alpha</i> -PW ₁₁ V ^V O ₄₀] \cdot 2H ₂ O	3.27	≈	--	-
6	K ₅ [<i>alpha</i> -1,2-PW ₁₀ V ₂ ^V O ₄₀] \cdot 3H ₂ O	1.64	-	-	-
7	K ₆ [<i>alpha</i> -1,2,3-PW ₉ V ₃ ^V O ₄₀] \cdot 4H ₂ O	1.11	≈	--	≈
8	K ₈ H[<i>alpha</i> -1,2,3-P ₂ W ₁₅ V ₃ ^V O ₆₂] \cdot 4H ₂ O	1.10	-	-	≈
9	K ₆ [<i>alpha</i> -1,4,9-PW ₉ V ₃ ^V O ₄₀] \cdot 4H ₂ O	1.08	-	--	≈
10	K ₈ [<i>alpha</i> -1,2-P ₂ W ₁₆ V ₂ ^V O ₆₂] \cdot 9H ₂ O	1.68	-	--	-
11	Na ₆ [V ₁₀ O ₂₈] \cdot 14H ₂ O	0.33	--	-	-
12	K ₅ [<i>alpha</i> -PW ₁₁ V ^V O ₄₀] \cdot 12H ₂ O	3.23	≈	--	≈
13	K ₈ [<i>alpha</i> -P ₂ W ₁₇ V ^V O ₆₂] \cdot 14H ₂ O	3.23	≈	--	--
14	K ₇ [<i>alpha</i> -P ₂ W ₁₇ V ^V O ₆₂] \cdot 11H ₂ O	3.19	--	-	≈
15	NaVO ₃	3.28			
			+ superior - inferior	+ stronger, - weaker effect	- more important loss

upon tungstate treatment. Very recently, the regeneration of pancreatic beta-cell population in diabetic rats treated orally with sodium tungstate was reported. (105)

In comparison to mononuclear complexes, polyoxometalates have been far less studied in the context of diabetes. The most systematic work was done by Nomiya and his colleagues, (106) who examined the insulin-mimetic effect of a series of fourteen compounds, mostly polyoxotungstates and vanadium-substituted polyoxotungstates (Table 3). The data were obtained with groups comprising mostly 2-4 mice, who showed individual variability. The compounds were dissolved in the drinking solutions, to which the mice had free access. The consumption of the solutions differed strongly between the groups. On the fourth day, the sample solutions were replaced with pure drinking water. The blood glucose level and the body weight were monitored over ten days. In several groups, the variations were rather irregular. In Table 3 are compiled some trends which can be seen: i) the variation in the blood glucose level compared to an untreated group, ii) the effect on the blood glucose level and iii) the effect on the body weight of each compound relative to that of NaVO₃. It should be noted that the authors started their work with the hypothesis that the active component in their compounds was vanadium. They therefore adjusted the concentrations of each complex such that the vanadium concentration was constant (except for homopolyoxotungstates). It can be seen from Table 3 that most polyoxometalates lower the blood glucose level, but only K₆[*alpha*-P₂W₁₈O₆₂] (entry 2) seems to perform better than NaVO₃. One must notice that the positive effect of K₆[*alpha*-P₂W₁₈O₆₂] was only occurring after three days. Before that, an increase in the blood glucose level was observed. Neither the structure nor the composition of the POMs seem to correlate with the lowering of glucose. This means that not the total vanadium content, but the intrinsic properties of each POM are responsible for the observed

effect. Among the polyoxotungstates lowering noticeably the glucose level, those with a Dawson structure (entries 2, 8, 14) produce no or little body weight loss. The authors showed furthermore by ³¹P NMR that [*alpha*-P₂W₁₈O₆₂]⁶⁻ is stable at mM concentrations in water. Although these results need to be put on a larger basis, they show clearly that polyoxometalates have a potential in diabetes treatment.

5. CELL PENETRATION

POMs are large (in the nanometer size range) and highly negatively charged species. These two factors certainly don't facilitate their penetration into cells. One might therefore conclude that the observed activities result from the interaction of the POMs with the cell surface. Some studies however indicate that under certain circumstances, POMs can cross the barrier and penetrate inside a cell. Cibert and Jasmin have incubated C3HBI fibroblasts with (NH₄)₁₇Na[NaW₂₁Sb₉] (HPA-23) at 3 \cdot 10⁻⁶ M. (107) They found a cytoplasmic precipitate which they analyzed by Raman Laser microscopy. POMs have intense IR and Raman bands for the W-O-W and W=O stretching vibrations. In the present case, a Raman band at 947 cm⁻¹ of the cytoplasmic precipitate can be attributed to the intact [NaW₂₁Sb₉]¹⁸⁻ ion (937 cm⁻¹ in (NH₄)₁₇Na[NaW₂₁Sb₉]). X-fluorescence microscopy was used to locate the polyoxotungstate in the treated cells. The authors concluded that HPA-23 enters the cells, but is not localized at any particular organelle.

Boudinot and his coworkers studied the uptake of K₁₂H₂[P₂W₁₂O₄₈], K₁₀[Zn₄(H₂O)₂(PW₉O₃₄)₂], [(CH₃)₃NH]₈[Si₂W₁₈Nb₆O₇₇] and (NH₄)₁₇Na[NaW₂₁Sb₉] in the macrophage cell line J774. (108) This type of white blood cell is responsible for the removal of a range of polyanionic substances including modified albumin and acetylated low density lipoprotein (LDL). The presence of 15 μg/mL of

Biomedical Applications of Polyoxometalates

any of the above polyoxotungstates reduced the endocytosis of acetylated LDL by approximately 50%. This indicates that LDL and polyoxotungstates are competing for the macrophage receptors. Also, more vacuoles were observed under fluorescence microscopy in the cells after incubation with polyoxotungstates. A Transmission-Electron-Microscopy analysis of $[(\text{CH}_3)_3\text{NH}]_8[\text{Si}_2\text{W}_{18}\text{Nb}_6\text{O}_{77}]$ treated cells revealed the presence of highly dense granules inside these vacuoles. This suggests the endocytosis of $[(\text{CH}_3)_3\text{NH}]_8[\text{Si}_2\text{W}_{18}\text{Nb}_6\text{O}_{77}]$ by J774 macrophages, although the combination with energy dispersive X-ray microanalysis could not establish the composition of these granules.

Yamase and his coworkers analyzed the metal content in dried bacteria cells incubated with polyoxometalates (see above 4.3). (74) They found a significant amount of tungsten, and less molybdenum and vanadium. For two compounds, $\text{K}_7[\text{PTi}_2\text{W}_{10}\text{O}_{40}]$ and $\text{K}_6[\text{P}_2\text{W}_{18}\text{O}_{62}]$, they established their distribution between the cell wall, the cytoplasm and the membrane fraction of the cell lysate. Both compounds are associated with the membrane fraction, but this technique does not allow to conclude if the polyoxotungstates were inside the cell.

6. CONCLUSIONS

The diversity of polyoxometalates is reflected in the diversity of their biomedical applications, but the largest efforts have been so far devoted to the study of their antiviral, antitumoral and antibiotic properties. No polyoxometalate has been developed to the stage of a drug in clinical use. Their toxicity is certainly a major drawback. Several authors documented toxic side effects of polyoxometalates. (109, 110) However, several *in vivo* studies (vide supra) show that the administration of polyoxometalates is possible without acute toxic effects. The gap between a useful drug and a toxic substance is very narrow, and every chemist knows that small derivatizations can change the properties of compounds dramatically. Therefore further research on polyoxometalates in medicine is necessary.

7. REFERENCES

1. Baker, L. C. W. and D. C. Glick: Present General Status of Understanding of Heteropoly Electrolytes and a Tracing of Some Major Highlights in the History of Their Elucidation. *Chemical Reviews* 98, 3-49 (1998)
2. Pope, M. T: Heteropoly and Isopoly Oxometalates. Springer Verlag, Berlin, (1983)
3. Pope, M. T. and A. Müller: Polyoxometalates: From Platonic Solids to Anti-Retroviral Activity. Kluwer Academic Publishers, Dordrecht.(1994)
4. Pope, M. T. and A. Müller: Polyoxometalate Chemistry: From Topology via Self-Assembly to Applications. Kluwer Academic Publishers, Dordrecht (2001)
5. Polyoxometalate Molecular Science. Eds: J. J. Borrás-

Almenar, E. Coronado, A. Müller and M. T. Pope, Kluwer Academic Publishers, Dordrecht (2003)

6. Casan Pastor, N. and P. Gomez Romero: Polyoxometalates: From Inorganic Chemistry to Materials Science. *Frontiers in Bioscience* 9, 1759-1770 (2004)

7. Special issue on polyoxometalates: Polyoxometalates. *Chemical Reviews* 98 (1998)

8. Guo, Z. and P. J. Sadler: Medicinal inorganic chemistry. *Advances in Inorganic Chemistry* 49, 183-306 (2000)

9. Tajima, Y: A review of the biological and biochemical effects of tungsten compounds. *Current Topics in Biochemical Research* 4, 129-136 (2001)

10. Rhule, J. T., C. L. Hill, D. A. Judd and R. F. Schinazi: Polyoxometalates in Medicine. *Chemical Reviews* 98, 327-357 (1998)

11. Souchay, P: Polyanions et Polycations. Gauthiers-Villars, Paris (1963)

12. Souchay, P: Ions Minéraux Condensés. Masson, Paris (1969)

13. Jolivet, J.-P: Metal Oxide Chemistry and Synthesis: From Solution to Solid State. John Wiley & Sons, New York (2001)

14. Pope, M. T: Molybdenum Oxygen Chemistry: Oxides, Oxo Complexes, and Polyoxoanions. In: Progress in Inorganic Chemistry. Ed: S. J. Lippard, John Wiley & Sons, New York, 181-255 (1991)

15. Hervé, G., A. Tézé and R. Contant: General Principles of the Synthesis of Polyoxometalates in Aqueous Solution. In: Polyoxometalate Molecular Science. Eds: J. J. Borrás-Almenar, E. Coronado, A. Müller and M. T. Pope, Kluwer Academic Publishers, Dordrecht, 33-54 (2003)

16. Errington, R. J: General Strategies for Non-Aqueous Polyoxometalate Synthesis. In: Polyoxometalate Molecular Science. Eds: J. J. Borrás-Almenar, E. Coronado, A. Müller and M. T. Pope, Kluwer Academic Publishers, Dordrecht, 55-78 (2003)

17. Klemperer, W. G: Early Transition Metal Polyoxoanions. In: Inorganic Syntheses. Ed. A. P. Ginsberg, John Wiley & Sons, New York, 71-135 (1990)

18. Müller, A. and P. Kögerler: From simple building blocks to structures with increasing size and complexity. *Coordination Chemistry Reviews* 182, 3-17 (1999)

19. Pope, M. T: Introduction to Polyoxometalate Chemistry. In: Polyoxometalate Molecular Science. Eds: J. J. Borrás-Almenar, E. Coronado, A. Müller and M. T. Pope, Kluwer Academic Publishers, Dordrecht, 3-31 (2003)

20. Hill, C. L: Stable, self-assembling, equilibrating catalysts for green chemistry. *Angewandte Chemie*,

Biomedical Applications of Polyoxometalates

International Edition 43, 402-404 (2004)

21. Wei, X., M. H. Dickman and M. T. Pope: Rhodium-Carbon Bond Formation in Aqueous Solution. Synthesis, Structure, and Reactivity of the Functionalized Heteropolytungstates $[XW_{11}O_{39}RhCH_2COOH]^{5,6-}$ (X = P, Si). *Journal of the American Chemical Society* 120, 10254-10255 (1998)

22. Bareyt, S., S. Piligkos, B. Hasenknopf, P. Gouzerh, E. Lacôte, S. Thorimbert and M. Malacria: Highly efficient peptide bond formation to functionalized Wells-Dawson-type polyoxotungstates. *Angewandte Chemie, International Edition* 42, 3404-3406 (2003)

23. Gouzerh, P. and A. Proust: Main-Group Element, Organic, and Organometallic Derivatives of Polyoxometalates. *Chemical Reviews* 98, 77-112 (1998)

24. Hasenknopf, B., R. Delmont, P. Herson and P. Gouzerh: Anderson-type heteropolymolybdates containing tris(alkoxo) ligands: Synthesis and structural characterization. *European Journal of Inorganic Chemistry* 1081-1087 (2002)

25. Mayer, C. R., P. Herson and R. Thouvenot: Organic-Inorganic Hybrids Based on Polyoxometalates. 5. Synthesis and Structural Characterization of Bis(organophosphoryl) decatungstosilicates $[\gamma-SiW_{10}O_{36}(RPO)_2]^{4-}$. *Inorganic Chemistry* 38, 6152-6158 (1999)

26. Mazeaud, A., Y. Dromzee and R. Thouvenot: Organic-Inorganic Hybrids Based on Polyoxometalates. 6. Syntheses, Structure, and Reactivity of the Bis(tertbutylsilyl)decatungstophosphate $[(\gamma-PW_{10}O_{36})(tBuSiOH)_2]^{3-}$. *Inorganic Chemistry* 39, 4735-4740 (2000)

27. Kortz, U., J. Vaissermann, R. Thouvenot and P. Gouzerh: Heteropolymolybdates of Phosphate, Phosphonate, and Phosphite Functionalized by Glycine. *Inorganic Chemistry* 42, 1135-1139 (2003)

28. Bustos, C., B. Hasenknopf, R. Thouvenot, J. Vaissermann, A. Proust and P. Gouzerh: Lindqvist-type (aryldiazenido)polyoxomolybdates - synthesis, and structural and spectroscopic characterization of compounds of the type $(^tBu_4N)_3[Mo_6O_{18}(N_2Ar)]$. *European Journal of Inorganic Chemistry* 2757-2766 (2003)

29. Proust, A., R. Villanneau, R. Delmont, V. Artero and P. Gouzerh: Organometallic oxometal clusters. In: *Polyoxometalate Chemistry*. Eds: M. T. Pope and A. Müller, Kluwer Academic Publishers, Dordrecht, 55-67 (2001)

30. Chermann, J. C., M. Raynaud, C. Jasmin and G. Mathé: Powerful new inhibitor of murine leukaemia and sarcoma viruses. *Nature* 227, 173-174 (1970)

31. Raynaud, M., J.-C. Chermann, C. Jasmin and G. Mathé: Propriétés d'un inhibiteur très actif des virus leucémogènes murins. *Comptes Rendus Hebdomadaires Des Séances De*

L'Academie Des Sciences. D: Sciences Naturelles 270, 578-580 (1970)

32. Raynaud, M., J.-C. Chermann, F. Plata, C. Jasmin and G. Mathé: Inhibiteurs des virus du groupe leucémie-sarcome murins. Silicotungstates. *Comptes Rendus Hebdomadaires Des Séances De L'Academie Des Sciences. D: Sciences Naturelles* 272, 347-348 (1971)

33. Bonissol, C., P. Kona, J. C. Chermann, C. Jasmin and M. Raynaud: Antiviral action of condensed mineral polyanions. *In vitro* inhibition of rubella virus. *Comptes Rendus Hebdomadaires Des Séances De L'Academie Des Sciences. D: Sciences Naturelles* 274, 3030-3033. (1972)

34. Raynaud, N., C. Jasmin, J. Huppert, J. C. Chermann, G. Mathé and M. Raynaud: Study of antiviral activity of mineral condensed polyanions. II. Effect on vesicular stomatitis virus. *Revue européenne d'études cliniques et biologiques* 17, 295-299. (1972)

35. Haapala, D. K., C. Jasmin, F. Sinoussi, J. C. Chermann and M. Raynaud: Inhibition of tumor virus RNA-dependent DNA polymerase by the heteropolyanion silicotungstate. *Biomedicine* 19, 7-11 (1973)

36. Jasmin, C., N. Raynaud, J. C. Chermann, D. Haapala, F. Sinoussi, C. B. Loustau, C. Bonissol, P. Kona and M. Raynaud: *In vitro* effects of silicotungstate on some RNA viruses. *Biomedicine* 18, 319-327 (1973)

37. Jasmin, C., J. C. Chermann, N. Raynaud, D. Bucchini, O. Jarrett, M. Raynaud, G. Mathé and F. Plata: Effects of STAS JLSV5 and silicotungstate on the replication of murine sarcoma virus (Moloney) and poliovirus. *Bibliotheca Haematologica* 39, 381-388 (1973)

38. Larnicol, N., Y. Augery, C. Le Bousse-Kerdiles, V. Degiorgis, J. C. Chermann, A. Tézé and C. Jasmin: *In vivo* effect of a new mineral condensed ion (HPA 39) on murine Friend leukemia. *Journal of General Virology* 55, 17-23 (1981)

39. Jasmin, C., J. C. Chermann, G. Herve, A. Teze, P. Souchay, C. Boy-Loustau, N. Raynaud, F. Sinoussi and M. Raynaud: *In vivo* inhibition of murine leukemia and sarcoma viruses by the heteropolyanion 5-tungsto-2-antimonate. *Journal of the National Cancer Institute (1940/1978)* 53, 469-474 (1974)

40. Chermann, J. C., F. C. Sinoussi and C. Jasmin: Inhibition of RNA-dependent DNA polymerase of murine oncornaviruses by ammonium-5-tungsto-2-antimonate. *Biochemical and Biophysical Research Communications* 65, 1229-1236 (1975)

41. Raynaud, N., J. C. Chermann, F. C. Sinoussi, Y. Augery and C. Jasmin: Studies on the mechanism of action of ammonium-5-tungsto-2-antimonate (HPA 23). *Bibliotheca Haematologica* 504-507 (1975)

42. Werner, G. H., C. Jasmin and J. C. Chermann: Effect of

Biomedical Applications of Polyoxometalates

- ammonium 5-tungsto-2-antimoniate on encephalomyocarditis and vesicular stomatitis virus infections in mice. *Journal of General Virology* 31, 59-64 (1976)
43. Tsiang, H., P. Atanasiu, J. C. Chermann and C. Jasmin: Inhibition of rabies virus *in vitro* by the ammonium-5-tungsto-2-antimoniate. *Journal of General Virology* 40, 665-668 (1978)
44. Souyri-Caporale, M., M. G. Tovey, K. Ono, C. Jasmin and J. C. Chermann: Modulation by the polyoxotungstate HPA-23 of Epstein-Barr virus early antigen expression in Raji cells treated with iododeoxyuridine. *Journal of General Virology* 65, Pt 4, 831-835 (1984)
45. Rozenbaum, W., D. Dormont, B. Spire, E. Vilmer, M. Gentilini, C. Griscelli, L. Montagnier, F. Barre-Sinoussi and J. C. Chermann: Antimoniotungstate (HPA 23) treatment of three patients with AIDS and one with prodrome. *Lancet* 1, 450-451 (1985)
46. Rhule, J. T., C. L. Hill, Z. Zheng and R. F. Schinazi: Polyoxometalates and fullerenes as antiHIV agents. *Topics in Biological Inorganic Chemistry* 2, 117-137 (1999)
47. Witvrouw, M., H. Weigold, C. Pannecouque, D. Schols, E. De Clercq and G. Holan: Potent Anti-HIV (Type 1 and Type 2) Activity of Polyoxometalates: Structure-Activity Relationship and Mechanism of Action. *Journal of Medicinal Chemistry* 43, 778-783 (2000)
48. Shigeta, S., S. Mori, E. Kodama, J. Kodama, K. Takahashi and T. Yamase: Broad spectrum anti-RNA virus activities of titanium and vanadium substituted polyoxotungstates. *Antiviral Research* 58, 265-271 (2003)
49. Judd, D. A., J. H. Nettles, N. Nevins, J. P. Snyder, D. C. Liotta, J. Tang, J. Ermolieff, R. F. Schinazi and C. L. Hill: Polyoxometalate HIV-1 protease inhibitors. A new mode of protease inhibition. *Journal of the American Chemical Society* 123, 886-897 (2001)
50. Yamamoto, N., D. Schols, E. De Clercq, Z. Debyser, R. Pauwels, J. Balzarini, H. Nakashima, M. Baba and M. Hosoya: Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents. *Molecular Pharmacology* 42, 1109-1117 (1992)
51. Yamase, T: Polyoxometalates for molecular devices: antitumor activity and luminescence. *Molecular Engineering* 3, 241-262 (1993)
52. Yamase, T., H. Fujita, K. Fukushima and Y. Seto: In: *PCT Int. Appl* 68, Terumo Corp., Japan, Wo, (1988)
53. Yamase, T., H. Fujita and K. Fukushima: Medical chemistry of polyoxometalates. Part 1. Potent antitumor activity of polyoxomolybdates on animal transplantable tumors and human cancer xenograft. *Inorganica Chimica Acta* 151, 15-18 (1988)
54. Fujita, H., T. Fujita, T. Sakurai, T. Yamase and Y. Seto: Antitumor activity of new antitumor substance, polyoxomolybdate, against several human cancers in athymic nude mice. *Tohoku Journal of Experimental Medicine* 168, 421-426 (1992)
55. Tomita, K., T. Yamase and K. Shishido: Medical chemistry of polyoxometalates. Part 2. Enzymatic study on binding of heptamolybdate to DNA. *Inorganica Chimica Acta* 157, 167-169 (1989)
56. Yamase, T: Anticancer agents containing heteropolytungstate ethers. *Jpn. Kokai Tokkyo Koho*, Terumo Corp., Japan, Jp 02204416, (1990)
57. Yamase, T: Heteropolyacid salt esters as antitumor agents. *Jpn. Kokai Tokkyo Koho*, Terumo Corp., Japan, Jp 02083328, (1990)
58. Yamase, T., H. Fujita, K. Fukushima and T. Sakurai: Anticancer agents containing heteropolytungstates. *Jpn. Kokai Tokkyo Koho*, Terumo Corp., Japan, Jp 02204415, (1990)
59. Yamase, T., H. Fujita, K. Fukushima and T. Sakurai: Heteropolyacid salts as antitumor agents. *Jpn. Kokai Tokkyo Koho*, Terumo Corp., Japan, Jp 02088524, (1990)
60. Liu, J.-F., Y.-G. Chen, L. Meng, J. Guo, Y. Liu and M. T. Pope: Synthesis and characterization of novel heteropoly-tungstoarsenates containing lanthanides $[\text{LnAs}_4\text{W}_{40}\text{O}_{140}]^{25-}$ and their biological activity. *Polyhedron* 17, 1541-1546 (1998)
61. Wang, X.-H., J.-F. Liu, Y.-G. Chen, Q. Liu, J.-T. Liu and M. T. Pope: Synthesis, characterization and biological activity of organotitanium substituted heteropolytungstates. *Dalton* 1139-1142 (2000)
62. Wang, X., J. Liu and J. Li: Synthesis, characterization and *in vitro* antitumor activity of diorganometallo complexes gamma-Keggin anions. *Inorganic Chemistry Communications* 4, 372-374 (2001)
63. Wang, X.-H., H.-C. Dai and J.-F. Liu: Synthesis, properties and biological activity of organotin decatungstophosphates, Part 2. *Transition Metal Chemistry* 24, 600-604 (1999)
64. Wang, X., J. Liu and M. T. Pope: New polyoxometalate/starch nanomaterial: synthesis, characterization and antitumor activity. *Dalton Transactions* 957-960 (2003)
65. Wang, X., J. Liu, J. Li, Y. Yang, J. Liu, B. Li and M. T. Pope: Synthesis and antitumor activity of cyclopentadienyltitanium substituted polyoxotungstate $[\text{CoW}_{11}\text{O}_{39}(\text{CpTi})]^{7-}$ (Cp= $\eta^5\text{-C}_5\text{H}_5$). *Journal of Inorganic Biochemistry* 94, 279-284 (2003)
66. Wang, X. H. and J. F. Liu: Synthesis and

Biomedical Applications of Polyoxometalates

characterization of organotin substituted heteropolytungstophosphates and their biological activity. *Journal of Coordination Chemistry* 51, 73-82 (2000)

67. Wang, X. H., H. C. Dai and J. F. Liu: Synthesis and characterization of organotin-substituted heteropolytungstosilicates and their biological activity I. *Polyhedron* 18, 2293-2300 (1999)

68. Wang, X., J. Li, J. He and J. Liu: Synthesis, properties and biological activity of organotitanium substituted heteropolytungstates. *Metal-Based Drugs* 8, 179-182 (2001)

69. Material and Safety Data Sheet, <http://www.sigmaaldrich.com> (Accessed: July 14, 2004)

70. Tajima, Y., Z. Nagasawa and J. Tadano: A factor found in aged tungstate solution enhanced the antibacterial effect of beta-lactams on methicillin-resistant *Staphylococcus aureus*. *Microbiology and Immunology* 37, 695-703 (1993)

71. Tajima, Y., Z. Nagasawa, I. Tanabe, K. Kusaba and J. Tadano: Possible mechanism of action of beta-lactam-enhancing factor on methicillin-resistant *Staphylococcus aureus*. *Microbiology and Immunology* 38, 639-648 (1994)

72. Tajima, Y: Purification of a factor that enhances the antibacterial activity of beta-lactams against methicillin-resistant *Staphylococcus aureus*: its identification as undecaphosphotungstate. *Journal of Inorganic Biochemistry* 68, 93-99 (1997)

73. Yamase, T., N. Fukuda and Y. Tajima: Synergistic effect of polyoxotungstates in combination with beta-lactam antibiotics on antibacterial activity against methicillin-resistant *Staphylococcus aureus*. *Biological & Pharmaceutical Bulletin* 19, 459-465 (1996)

74. Fukuda, N., T. Yamase and Y. Tajima: Inhibitory effect of polyoxotungstates on the production of penicillin-binding proteins and beta-lactamase against methicillin-resistant *Staphylococcus aureus*. *Biological & Pharmaceutical Bulletin* 22, 463-470 (1999)

75. Tajima, Y: Lacunary-substituted undecatungstosilicates sensitize methicillin-resistant *Staphylococcus aureus* to beta-lactams. *Biological & Pharmaceutical Bulletin* 24, 1079-1084 (2001)

76. Tajima, Y: The sensitizing effects of undecatungstocobalto(II)silicate on methicillin-resistant *Staphylococcus aureus* to beta-lactams. *Biomedical Research* 23, 115-125 (2002)

77. Tajima, Y: Effects of tungstosilicate on strains of methicillin-resistant *Staphylococcus aureus* with unique resistant mechanisms. *Microbiology and Immunology* 47, 207-212 (2003)

78. Davies, J. W. and J. F. Collins: The induction of *Bacillus licheniformis* penicillinase by vanadate, molybdate and tungstate anions. *Biochimica Et Biophysica Acta* 217,

552-554 (1970)

79. Fukuda, N. and T. Yamase: *In vitro* antibacterial activity of vanadate and vanadyl compounds against *Streptococcus pneumoniae*. *Biological & Pharmaceutical Bulletin* 20, 927-930 (1997)

80. Yamase, T. and Y. Tajima: MRSA inhibitors containing Keggin-type heteropolytungstate ions. *Jpn. Kokai Tokkyo Koho*, Horitoronikusu Kk, Japan; Yamase Toshihiro, Jp 08073362, (1996)

81. Tajima, Y: Detection of highly resistant strains of methicillin-resistant *Staphylococcus aureus* using polyoxotungstates. *Biomedical Research* 23, 273-276 (2002)

82. Porte, D. Jr., R. S. Sherwin and A. Baron: *Ellenberg & Rifkin's Diabetes Mellitus*. McGraw Hill, New York, (2003)

83. *Experimental Models of Diabetes*. Ed: J. H. McNeill, CRC Press LLC, (1999)

84. Shechter, Y. and S. J. D. Karlsh: Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl (IV) ions. *Nature* 284, 556-558 (1980)

85. Meyerovitch, J., Z. Farfel, J. Sack and Y. Shechter: Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. Characterization and mode of action. *Journal of Biological Chemistry* 262, 6658-6662 (1987)

86. Heyliger, C. E., A. G. Tahiliani and J. H. McNeill: Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats. *Science* 227, 1474-1477 (1985)

87. Crans, D. C., J. J. Smee, E. Gaidamauskas and L. Yang: *The Chemistry and Biochemistry of Vanadium and the Biological Activities Exerted by Vanadium Compounds*. *Chemical Reviews* 104, 849-902 (2004)

88. Thompson, K. H: Vanadium and diabetes. *BioFactors* 10, 43-51 (1999)

89. Sakurai, H., H. Yasui and Y. Adachi: The therapeutic potential of insulin-mimetic vanadium complexes. *Expert Opinion on Investigational Drugs* 12, 1189-1203 (2003)

90. Crans, D. C: Chemistry and insulin-like properties of vanadium(IV) and vanadium(V) compounds. *Journal of Inorganic Biochemistry* 80, 123-131 (2000)

91. Shechter, Y., I. Goldwaser, M. Mironchik, M. Fridkin and D. Gefel: Historic perspective and recent developments on the insulin-like actions of vanadium; toward developing vanadium based drugs for diabetes. *Coordination Chemistry Reviews* 237, 3-11 (2003)

92. Goldwaser, I., D. Gefel, E. Gershonov, M. Fridkin and Y. Shechter: Insulin-like effects of vanadium: basic and clinical implications. *Journal of Inorganic Biochemistry* 80, 21-25 (2000)

Biomedical Applications of Polyoxometalates

93. Srivastava, A. K: Anti-diabetic and toxic effects of vanadium compounds. *Molecular and Cellular Biochemistry* 206, 177-182 (2000)
94. Thompson, K. H., J. H. McNeill and C. Orvig: Vanadium Compounds as Insulin Mimics. *Chemical Reviews* 99, 2561-2571 (1999)
95. Cam, M. C., R. W. Brownsey and J. H. McNeill: Mechanisms of vanadium action: insulinmimetic or insulin-enhancing agent? *Canadian Journal of Physiology and Pharmacology* 78, 829-847 (2000)
96. Goldfine, A. B., M.-E. Patti, L. Zuberi, B. J. Goldstein, R. LeBlanc, E. J. Landaker, Z. Y. Jiang, G. R. Willsky and C. R. Kahn: Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: *in vivo* and *in vitro* studies. *Metabolism, Clinical and Experimental* 49, 400-410 (2000)
97. Boden, G., X. Chen, J. Ruiz, G. D. V. van Rossum and S. Turco: Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. *Metabolism, Clinical and Experimental* 45, 1130-1135 (1996)
98. Fillat, C., J. E. Rodriguez-Gil and J. J. Guinovart: Molybdate and tungstate act like vanadate on glucose metabolism in isolated hepatocytes. *Biochemical Journal* 282, 659-663 (1992)
99. Munoz, M. C., A. Barbera, J. Dominguez, J. Fernandez-Alvarez, R. Gomis and J. J. Guinovart: Effects of tungstate, a new potential oral antidiabetic agent, in Zucker diabetic fatty rats. *Diabetes* 50, 131-138 (2001)
100. Barbera, A., R. R. Gomis, N. Prats, J. E. Rodriguez-Gil, M. Domingo, R. Gomis and J. J. Guinovart: Tungstate is an effective antidiabetic agent in streptozotocin-induced diabetic rats: a long-term study. *Diabetologia* 44, 507-513 (2001)
101. Barbera, A., J. Fernandez-Alvarez, A. Truc, R. Gomis and J. J. Guinovart: Effects of tungstate in neonatally streptozotocin-induced diabetic rats: Mechanism leading to normalization of glycemia. *Diabetologia* 40, 143-149 (1997)
102. Fierabracci, V., V. De Tata, A. Pocai, M. Novelli, A. Barbera and P. Masiello: Oral tungstate treatment improves only transiently alteration of glucose metabolism in a new rat model of type 2 diabetes. *Endocrine* 19, 177-184 (2002)
103. Foster, J. D., S. E. Young, T. D. Brandt and R. C. Nordlie: Tungstate: a potent inhibitor of multifunctional glucose-6-phosphatase. *Archives of Biochemistry and Biophysics* 354, 125132 (1998)
104. Dominguez, J. E., M. C. Munoz, D. Zafra, I. Sanchez-Perez, S. Baque, M. Caron, C. Mercurio, A. Barbera, R. Perona, R. Gomis and J. J. Guinovart: The antidiabetic agent sodium tungstate activates glycogen synthesis through an insulin receptor-independent pathway. *Journal of Biological Chemistry* 278, 42785-42794 (2003)
105. Fernandez-Alvarez, J., A. Barbera, B. Nadal, S. Barcelo-Batllo, S. Piquer, M. Claret, J. J. Guinovart and R. Gomis: Stable and functional regeneration of pancreatic beta-cell population in nSTZ-rats treated with tungstate. *Diabetologia* 47, 470-477 (2004)
106. Nomiya, K., H. Torii, T. Hasegawa, Y. Nemoto, K. Nomura, K. Hashino, M. Uchida, Y. Kato, K. Shimizu and M. Oda: Insulin mimetic effect of a tungstate cluster. Effect of oral administration of homo-polyoxotungstates and vanadium-substituted polyoxotungstates on blood glucose level of STZ mice. *Journal of Inorganic Biochemistry* 86, 657-667 (2001)
107. Cibert, C. and C. Jasmin: Determination of the intracellular localization of a polyoxotungstate (HPA-23) by Raman laser and x-fluorescence spectroscopies. *Biochemical and Biophysical Research Communications* 108, 1424-1433 (1982)
108. Lan, N., P. Greenspan, R. Gutman, C. Kelloes, M. A. Farmer and F. D. Boudinot: Cellular localization of antiviral polyoxometalates in J774 macrophages. *Antiviral Research* 32, 141148 (1996)
109. Domingo, J. L: Vanadium and tungsten derivatives as antidiabetic agents: A review of their toxic effects. *Biological Trace Element Research* 88, 97-112 (2002)
110. Tajima, Y: Tungstophosphate induced thromboembolic complications *in vivo*. *Biomedical Research* 24, 39-49 (2003)

Footnotes: ¹ ILS = 100(t-c)/c, where t is the mean survival time of the treated group and c is the mean survival time of the control group. ² IC50 (50% inhibitory concentration) is the concentration that suppresses tumor cells by 50%. ³ The fractional inhibitory concentration (FIC) is an interaction coefficient indicating whether the combined inhibitory/bacteriostatic effect of drugs is synergistic, additive or antagonistic. FIC = A + B where A = (MIC of combination X + Y)/(MIC of drug X alone) B = (MIC of combination X + Y)/(MIC of drug Y alone) MIC (minimal inhibitory concentration) is the lowest concentration of an antibiotic that inhibits growth of >99% of the bacteria present. Interpretation: Synergistic: FIC smaller than or equal 0.5 Additive: FIC = 1 Antagonistic: FIC greater than or equal 4

Acknowledgements: I would like to express my deepest gratitude to Pierre Gouzerh for his unlimited support.

Key Words: Polyoxomolybdates, Polyoxotungstates, Polyoxovanadates, Infections, Cancer, Review

Send correspondence to: Dr Bernold Hasenknopf, Laboratoire de Chimie Inorganique et Matériaux Moléculaires, UMR CNRS 7071, Université Pierre et Marie Curie, 4 place Jussieu, 75252 Paris cedex 05, France, Tel: 33-1-4427-30-34, Fax: 33-1-4427-38-41, E-mail: hasen@ccr.jussieu.fr

<http://www.bioscience.org/current/vol10.htm>